OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function ...Middle East

PR Newswire - News
OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function
STOCKHOLM, June 11, 2021 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces completion of its pivotal Phase 3 study and reports top line results. OxThera's 52-week OC5-DB-02 study "A...

Hence then, the article about oxthera reports results from phase 3 ephex study with oxabact in primary hyperoxaluria patients with maintained kidney function was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News